sofidexFor patientsAre you a clinician? Clinical site

Health Library  ›  News  ›  Health notices · Friday 6 November

Updates ·

Health notices · Friday 6 November

3 notices from the agencies today, in plain words, each with the original linked.

About 2 minutes to readNoticePublished November 2026

PDF
a plain paper envelope and an unopened cardboard box on a table

FDA flags amlodipine/olmesartan tablets for Class II issue

FDA · Recall

If you take amlodipine and olmesartan medoxomil tablets (10mg/40mg), the US Food and Drug Administration reports a Class II issue.

The tablets were found out of specification because of dissolution results, and this was distributed nationwide in the United States.

The notice does not say what you should do next, but the product may be affected differently than expected.

Read the original notice

Duvyzat monitoring advice updated after reports of deaths

Medicines and Healthcare products Regulatory Agency (MHRA) · Safety

If you take Duvyzat (givinostat) for Duchenne muscular dystrophy (DMD), the MHRA has reviewed international reports of deaths and is advising interim risk mitigation while an independent review continues.

The MHRA proposes changes to product information focused on the heart rhythm risk linked to Duvyzat. This means additional heart checks (ECGs, including 24-hour monitoring) and blood tests for key minerals while you’re on treatment.

You should keep taking Duvyzat as prescribed and attend all appointments. Tell your specialist Duchenne team if you have concerns or if any medicines you take are added or changed.

What to do

  • Continue taking Duvyzat as prescribed and attend all appointments.
  • Tell your doctor about any additional medications you are taking or if they change.
  • Speak to your specialist Duchenne’s team if you have any concerns about your treatment.
  • Report ALL suspected adverse drug reactions associated with Duvyzat on the Yellow Card scheme.

Read the original notice

CDC updated nursing home COVID-19 and respiratory data dashboard

Centers for Disease Control and Prevention (CDC) · Guidance

If you live in, or work in, a Centers for Medicare & Medicaid Services (CMS)-certified nursing home, CDC’s Nursing Home Data Dashboard has been updated (November 5, 2026). The dashboard summarizes reports of COVID-19 and other respiratory viruses from nursing homes to CDC’s NHSN system.

The update includes weekly vaccination coverage, case rates (cases per 100,000 residents), and hospitalization rates (hospitalizations with a positive respiratory test), plus monthly COVID-19 vaccination data for nursing home healthcare personnel.

The dashboard is updated weekly on Thursdays at 8:00 AM, and some “preliminary data” are shown in gray. This may help you track how reported respiratory illness and vaccination trends are changing over time.

Read the original notice